BackCancer Genetics Overview

Cancer Genetics Other Current Liabilities

Cancer Genetics's other current liabilities is $690K.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$694000.00

Peer average / median

Loading

Cancer Genetics Other Current Liabilities History

Loading

Cancer Genetics vs. peers: Other Current Liabilities Comparison

Loading

Cancer Genetics Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Cancer Genetics (CGIX) FAQ

The latest other current liabilities for CGIX is $690K as of December 2020. Investors often review this figure alongside Cancer Genetics's historical trend and sector peers before judging valuation or financial health.

A other current liabilities figure of $690K for CGIX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting CGIX's other current liabilities ($690K), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Cancer Genetics's other current liabilities against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.